LITS (Lite Strategy) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


LITS Lite Strategy Inc LITS
22 GF Score
Price $0.85
! 2 Warning Signs
View Full Analysis

What is Lite Strategy Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Lite Strategy's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LITS vs DARE, ALGS, TVGN: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Lite Strategy's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lite Strategy Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lite Strategy's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Lite Strategy's Margin of Safety % (DCF Earnings Based) falls into.


LITS
22GF Score
Lite Strategy Inc LITS
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lite Strategy Business Description

Other Exchanges 0JW9:UK
Address 9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
22GF Score

Get the complete analysis for LITS

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.85
Price